EQT to Buy U.S. Digital Consultancy Perficient in $3 Billion Deal
By Dominic Chopping
STOCKHOLM--EQT will acquire U.S. digital consultancy Perficient in an all-cash deal valued at around $3 billion, the companies said late Sunday.
Swedish private-equity firm EQT said it will pay $76 a share, a 58% premium to Perficient's closing price of $48.11 on Friday.
"Today's announcement is the result of a comprehensive review by the board to maximize value for the company and its shareholders," said Jeffrey Davis, Perficient Chairman.
"With this agreement with EQT, we will provide our shareholders with compelling, certain cash value for their shares while continuing to support our clients."
St. Louis-based Perficient will be delisted from Nasdaq following completion, which is expected by the end of 2024.
The deal has been unanimously approved by Perficient's board and the companies said Tom Hogan will continue as chief executive while the current management team will also remain in place.
EQT said with the acquisition, its BPEA Private Equity Fund VIII is expected to be 55%-60% invested.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
May 06, 2024 02:10 ET (06:10 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks